Anderson, and N. expressing other PvDBPII alleles (age-adjusted hazard ratio, 0.75 [95% confidence interval, 0.56 to 1 1.00 by Cox regression]) and 39% lower incidence density parasitemia (= 0.01). Two other prevalent alleles (AH and P) showed a similar trend of 16% and 18% protection, respectively, against parasites with the same PvDBPII allele and reduced incidence density parasitemia. Antibodies directed to PvDBPII PNG-P and -O were both associated with a 21 to 26% reduction in the risk of infections with higher levels of parasitemia (>150 parasites/l), respectively. There was no association with high antibody levels to PvMSP119 and a delay in the time to reinfection. Thus, anti-PvDBPII antibodies are associated with strain-specific immunity to and support the use of PvDBPII for a vaccine against has been shown to increase with age in communities where is endemic, suggesting that a vaccine to may be possible (1, 27). However, naturally acquired immunity does not prevent infection but instead limits parasite densities and reduces severe disease and clinical symptoms. Humoral immune responses against blood-stage antigens are believed to be an important component of naturally acquired immunity to (12, 29). Malaria blood-stage vaccines aim to disrupt the interactions between ligands on the merozoite and the receptors on the host erythrocyte by eliciting inhibitory antibodies that target the merozoite ligands. Humoral immune responses to the merozoite antigens Duffy binding protein region II (PvDBPII) and merozoite surface protein 1 (PvMSP1) have Astragaloside A been implicated in acquired immunity to is endemic, and are potential vaccine candidate antigens (2, 21, 22, 24, 27, 28). However, few prospective studies of immune responses to antigens have been performed on human populations in areas where is endemicwe are aware of only one to PvMSP1 (16). Since PvDBPII interaction with the N-terminal extracellular region of Duffy antigen (DA) on host erythrocytes is essential for merozoite invasion, a prospective study of antibody responses to the PvDBPII antigen may lead to a better understanding of immune correlates of protection to into host erythrocytes in vitro (8). Importantly, children that acquire high levels of BIAbs show 55% reduction in the risk of infection (11). Antibodies directed to PvDBPII as measured by enzyme-linked immunosorbent assay (ELISA) also correlated with protection but less strongly than BIAbs (11). PvDBPII is highly polymorphic, however, and antibodies to different variants can inhibit the binding of homologous variants but have reduced Astragaloside A ability to block the binding of heterologous PvDBPII protein variants in vitro (11, 25). Immune responses Rabbit polyclonal to ERK1-2.ERK1 p42 MAP kinase plays a critical role in the regulation of cell growth and differentiation.Activated by a wide variety of extracellular signals including growth and neurotrophic factors, cytokines, hormones and neurotransmitters. of children with BIAbs that inhibit binding by >90% were usually strain transcending (11); however, responses of most children with BIAbs that inhibit binding by <90% were strain specific (11). Only a quarter of the children had detectable BIAbs using this assay (8), whereas more than 80% of the children had total antibody responses to PvDBPII. It is unknown whether antibodies to different PvDBPII haplotypes protect better against parasites with the same DBPII haplotype than parasites with a different PvDBPII haplotype. Since BIAbs correlated with total antibodies to PvDBPII (11) and there were an insufficient number of children with BIAbs, we examined the hypothesis that naturally acquired total strain-specific PvDBPII antibodies are associated with greater protection against the homologous versus heterologous strains. In order to determine if host immunity toward a specific PvDBPII variant increases the time to reinfection with that variant, we followed 206 Papua New Guinean children (mean age, 9.4 years; range, 4 to 14 Astragaloside A years) biweekly for 6 months after treatment to clear their blood-stage malaria infections. Astragaloside A Prior to treatment, antibody levels were measured by ELISA to five different PvDBPII variants present in the population, and erythrocyte membrane protein 1 (PfEBA175-F2, an ortholog to PvDBPII and an.